UZH-Logo

Maintenance Infos

Aglepristone decreases proliferation in progesterone receptor-positive canine mammary carcinomas


Guil-Luna, S; Sánchez-Céspedes, R; Millán, Y; De Andrés, F J; Rollón, E; Domingo, V; Guscetti, F; Martín de Las Mulas, J (2011). Aglepristone decreases proliferation in progesterone receptor-positive canine mammary carcinomas. Journal of Veterinary Internal Medicine, 25(3):518-523.

Abstract

BACKGROUND:

Progesterone receptor (PR) antagonist aglepristone (RU534) has been used successfully for pregnancy termination and therapy of pyometra, vaginal tumors, and mammary hyperplasia in bitches and queens. All of these conditions share with canine mammary carcinomas the expression of PR.
OBJECTIVES:

To study the effect of RU534 on proliferation and apoptosis in canine mammary carcinomas in relation to PR expression.
ANIMALS:

Twenty-seven nonspayed bitches with mammary carcinomas were treated with either 2 doses of 20 mg/kg RU534 (n = 22, RU534-treated group) or oil placebo (n = 5, control group) on days 1 and 8.
METHODS:

Tumor samples were collected before (day 1) and after (day 15) treatment for immunohistochemistry. PR expression, proliferation index (PI), and apoptotic index (AI) were determined using antibodies against PR, Ki67, and cleaved lamin A/C antigens, respectively. The effect of treatment on these parameters was analyzed.
RESULTS:

Differential expression of PR between day 1 (59.1% PR-positive tumors) and day 15 (36.4% PR-positive tumors) was observed in RU534-treated tumors exclusively. After RU534 treatment, mean PI was significantly decreased in PR-positive but unchanged in PR-negative RU534-treated tumors. A reduction of ≥20% in PI was found in 61.5% of RU534-treated tumors with PR expression. Conversely, no effect on AI was observed after RU534 treatment.
CONCLUSIONS AND CLINICAL IMPORTANCE:

Neoadjuvant RU534 treatment had PR expression-related inhibiting effects on proliferation of canine mammary carcinoma cells.

BACKGROUND:

Progesterone receptor (PR) antagonist aglepristone (RU534) has been used successfully for pregnancy termination and therapy of pyometra, vaginal tumors, and mammary hyperplasia in bitches and queens. All of these conditions share with canine mammary carcinomas the expression of PR.
OBJECTIVES:

To study the effect of RU534 on proliferation and apoptosis in canine mammary carcinomas in relation to PR expression.
ANIMALS:

Twenty-seven nonspayed bitches with mammary carcinomas were treated with either 2 doses of 20 mg/kg RU534 (n = 22, RU534-treated group) or oil placebo (n = 5, control group) on days 1 and 8.
METHODS:

Tumor samples were collected before (day 1) and after (day 15) treatment for immunohistochemistry. PR expression, proliferation index (PI), and apoptotic index (AI) were determined using antibodies against PR, Ki67, and cleaved lamin A/C antigens, respectively. The effect of treatment on these parameters was analyzed.
RESULTS:

Differential expression of PR between day 1 (59.1% PR-positive tumors) and day 15 (36.4% PR-positive tumors) was observed in RU534-treated tumors exclusively. After RU534 treatment, mean PI was significantly decreased in PR-positive but unchanged in PR-negative RU534-treated tumors. A reduction of ≥20% in PI was found in 61.5% of RU534-treated tumors with PR expression. Conversely, no effect on AI was observed after RU534 treatment.
CONCLUSIONS AND CLINICAL IMPORTANCE:

Neoadjuvant RU534 treatment had PR expression-related inhibiting effects on proliferation of canine mammary carcinoma cells.

Citations

11 citations in Web of Science®
10 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

3 downloads since deposited on 24 Jan 2012
0 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:05 Vetsuisse Faculty > Institute of Veterinary Pathology
Dewey Decimal Classification:570 Life sciences; biology
Language:English
Date:2011
Deposited On:24 Jan 2012 12:33
Last Modified:05 Apr 2016 15:25
Publisher:Wiley-Blackwell
ISSN:0891-6640
Publisher DOI:https://doi.org/10.1111/j.1939-1676.2011.0723.x
PubMed ID:21488964
Permanent URL: https://doi.org/10.5167/uzh-55911

Download

[img]
Content: Published Version
Filetype: PDF - Registered users only
Size: 941kB
View at publisher
[img]
Content: Accepted Version
Filetype: PDF - Registered users only
Size: 21MB

TrendTerms

TrendTerms displays relevant terms of the abstract of this publication and related documents on a map. The terms and their relations were extracted from ZORA using word statistics. Their timelines are taken from ZORA as well. The bubble size of a term is proportional to the number of documents where the term occurs. Red, orange, yellow and green colors are used for terms that occur in the current document; red indicates high interlinkedness of a term with other terms, orange, yellow and green decreasing interlinkedness. Blue is used for terms that have a relation with the terms in this document, but occur in other documents.
You can navigate and zoom the map. Mouse-hovering a term displays its timeline, clicking it yields the associated documents.

Author Collaborations